Try our corporate solution for free!
+1 (212) 419-5770

Leading pharmaceutical companies South Korea H1 2020, by revenue

Celltrion had the largest revenue among pharmaceutical companies in South Korea in the first half of 2020. Thanks in part to its COVID-19 antibody treatments, Celltrion saw its revenue grow by over 93 percent compared to the same period in the previous year. It was followed by Yuhan and Chong Kun Dang.

COVID-19 and Korean phramaceuticals

The global coronavirus pandemic badly affected Korean pharmaceutical companies. Most of them suffered from decreased revenues and losses because of poor overseas results from the pandemic, a drop in prescriptions as people avoided hospitals, ongoing legal challenges, and more. Celltrion, Yuhan, and Chong Kun Dang were a few of the companies that enjoyed increased revenues. Aside from Celltrion and its COVID-19 medication, Yuhan received over 35 million dollars in royalties, while Chong Kun Dang’s key products are medication for chronic illnesses such as diabetes. These drugs must be regularly and continuously consumed, so their sales continued despite the pandemic.

Pharmaceuticals in Korea

Leading Korean pharmaceutical companies include Hanmi Pharmaceutical, Chongkundang, Celltrion and others. Hanmi was the leading company with its production value of around 907 trillion won. Hanmi saw its revenues in the first half of 2020 drop by 50 percent compared to the same period in the previous year, mainly due to poor sales in the China market. Cardiovascular system drugs made up the leading therapeutic sector for Korean drugs in 2018, with a production value of over 3.5 trillion won. Central nervous system drugs came in second, followed by digestive and other metabolic drugs.

Leading pharmaceutical companies in South Korea in the 1st half of 2020, by revenue

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until October 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

August 2020


South Korea

Survey time period

H1 2020

Supplementary notes

Note: 1,000 South Korean won equal 0.84 U.S. dollars and 0.71 euros (as of August 2020).
Figures have been rounded.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical industry in South Korea"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.